Pharmaceutical News

RSS

POZEN announces Phase I study results of PA65020

POZEN Inc. announced today the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

28 Oct 2009

Mirafit fbcx reduces human body absorption of consumed fat

A scientific study to be presented today at the annual meeting of The Obesity Society will confirm significant weight loss using the pill mirafit fbcx®. Dr. K-L Catherine Jen and Dr. Joseph Artiss, principals at ArtJen Complexus USA, LLC, will present these clinical study findings today, October 27, at The Obesity Society 2009 annual scientific meeting at the Marriott Wardman Park Hotel in Washington, D.C., The Obesity Society's 27th annual scientific meeting.

28 Oct 2009

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

King Pharmaceuticals, Inc. announced today that it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.

28 Oct 2009

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage. Researchers and doctors remain puzzled as to what causes the wide range of reaction to Prozac and similar antidepressants.

28 Oct 2009

Medicines used for lowering blood cholesterol may be effective in the treatment of cancer

Millions of people around the world use medicines based on statins to lower their blood cholesterol, but new research from the University of Gothenburg, published in the prestigious journal PNAS, shows that statins may also be effective in the treatment of cancer.

27 Oct 2009

H1N1 overwhelms hospitals; Sebelius addresses flu vaccine shortage

Hospitals across the country are overwhelmed "as waves of flu patients arrive at their doors, doubling their emergency room volume," USA Today reports. "Just as significant is the effect on intensive care units: A relatively small number of flu patients are requiring intensive care, but some are so ill they will need round-the-clock care for weeks.

27 Oct 2009

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

PolyMedix completes second successful clinical study of PMX-60056

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

27 Oct 2009

Boston Medical Center deploys Fusionfx Immunization Management portal to manage H1N1 vaccination

Acknowledging the critical role of Centers for Disease Control and Prevention (CDC) guidelines in ensuring the safety and efficacy of H1N1 vaccinations, Carefx Corporation, a leading provider of interoperable workflow solutions to advance the quality and safety of patient care, today announced that Boston Medical Center (BMC) has deployed the Fusionfx Immunization Management portal designed to enter and track H1N1 vaccination administration history and support broad, community-wide immunization administration tracking.

27 Oct 2009

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Edmonton - Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009

CCPM coalition members urge Congress to fix or drop the current biogenerics provision

The Coalition for a Competitive Pharmaceutical Market (CCPM), its allied organizations, representing several hundred million Americans, join experts from the medical and research communities, economists and thought leaders appealing to Congress to fix the excessive 12-year market exclusivity and ever-greening provisions for biologics or drop it altogether.

27 Oct 2009

New anti-flu drugs to fight flu virus could become a reality

New anti-flu drugs could become a reality as a result of a study carried out by academics at the University of Hertfordshire.

27 Oct 2009

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

More teenagers are being vaccinated against human papillomavirus (HPV), meningococcal meningitis and pertussis (whooping cough), though the rates are still too low, according to recently released government data and a panel of experts convened by the National Foundation for Infectious Diseases (NFID).

27 Oct 2009

USAID and USP join to combat substandard and counterfeit medicines

With substandard and counterfeit versions of medicines intended to treat life-threatening diseases such as malaria, HIV/AIDS and tuberculosis posing a growing threat throughout the developing world, the U.S. Agency for International Development (USAID) and the U.S. Pharmacopeial Convention (USP) will expand their joint efforts to combat this menace by launching a new program over the next five years.

27 Oct 2009

HealthCore study shows Metanx tablets reduces health plan costs

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ-; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

Pharmaceutical News

POZEN announces Phase I study results of PA65020

Mirafit fbcx reduces human body absorption of consumed fat

Drug-cocktail approach offers hope in developing single agent to treat drug-resistant H1N1 swine flu

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

King Pharmaceuticals receives exclusive rights to market and sell CYANOKIT

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Medicines used for lowering blood cholesterol may be effective in the treatment of cancer

H1N1 overwhelms hospitals; Sebelius addresses flu vaccine shortage

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Astellas enters into agreement with Medivation to develop MDV3100

New systematic study for managing treatment-resistant bipolar depression

PolyMedix completes second successful clinical study of PMX-60056

Boston Medical Center deploys Fusionfx Immunization Management portal to manage H1N1 vaccination

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

CCPM coalition members urge Congress to fix or drop the current biogenerics provision

New anti-flu drugs to fight flu virus could become a reality

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

USAID and USP join to combat substandard and counterfeit medicines

HealthCore study shows Metanx tablets reduces health plan costs

LX211 may become the first approved oral treatment for modifying the course of uveitis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News